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In a  previous study a  technique  was reported for the purification  and frac- 
tionation  of human  antidextran  of al,6  specificity produced  in  a  single  in- 
dividual  into  two antibody  populations  with  distinctly  differing  affinities  for 
smaller versus larger oligosaccharides (1). The anfidextran, specifically absorbed 
onto an insoluble dextran (sephadex G-75), was eluted successively with haptens 
(cf. reference 2) of increasing size. Thus upon extraction  of the washed sepha- 
dex-antibody complex with isomaltose or isomaltotriose, followed by extensive 
dialysis of the extract to remove the oligosaccharides, an antibody fraction was 
obtained which was inhibited readily by small oligosaccharides, while a second 
fraction,  eluted subsequently with isomaltohexaose and  dialyzed,  consisted of 
antibody readily inhibitable by the larger oligosaccharides (1). These two frac- 
tions,  of similar  purity  with  respect  to  their  precipitability  by dextran,  con- 
tained only fast moving 7S gamma globulin,--as  did the purified human anti- 
dextran obtained by digestion of dextran-antidextran-specific  precipitates with 
dextranase,--and  showed by double diffusion in agar complete fusion both with 
antidextran  prepared with dextranase and with each other. These findings sup- 
ported  the earlier suggestion  (3)  that  antibody to one antigenic  determinant, 
the al, 6-1inked glucose chain in dextran,  produced in a  single individual,  con- 
sists of a  heterogenous  population  of molecules that  vary with respect to the 
sizes of their  antibody combining sites. 
Earlier  data  on  these  purified  antidextran  fractions  (1)  were  obtained  by 
quantitative  precipitin  and inhibition  assays using the ninhydrin  method with 
about 3 to 4 #g AbN per analysis. More recently prepared antidextran  fractions 
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have  now been  assayed  by the  quantitative  microcomplement  fixation  tech- 
nique of Wasserman and Levine (4). Small amounts of the earlier fractions (I) 
were  also  available.  The  findings  indicate  that  purified  human  antidextran 
fractions fix complement in presence of dextran and that the antibody extracted 
by the smaller oligosaccharides was less effective per unit N  than was the anti- 
body  extractable  by  the  larger  oligosaccharides.  The  relative  capacities  of 
oligosaccharides  of the  isomaltose  series  to inhibit  complement  fixation  with 
the two antibody fractions strikingly parallel  those found by assays using in- 
hibition of precipitation.  With the experience gained from complement fixation 
assays with purified antibody, conditions were determined under which several 
human antidextran  sera could be shown to fix guinea pig complement and the 
complement-fixing properties of antidextran  in serum and in the purified anti- 
body fractions were studied. 
EXPERIMENTAL 
Antidextran  Sera.--Three bleedings, (Dn,  Dn,  Dr,) from  subject  20 were available and 
used for antibody purification and fractionation.  Data on earlier bleedings and purified frac- 
tions were published previously (3, 5, 6, 1). For complement fixation studies on whole anti- 
dextran sera recent bleedings from subjects 20, 176, and J. H. were first heat-inactivated  at 
56°C for 30 minutes, then stored in small aliquots in the frozen state. Sera stored in the presence 
of phenol and merthiolate became anticomplementary.  Serum 176 D~ required absorption of 
hemolysin for 10 minutes at 4°C with washed sheep cells. 
Purification and Fraaionation of Antidextran.-- 
(a)  Absorption: The technique was essentially as published previously (1): to 550 ml of 
pooled  20  Du-~2 serum, clarified by prolonged centrifugation  in the cold and containing  a 
total of 9 mg of antibody N, in three 250 ml centrifuge bottles, 500 mg washed sephadex G-75 
(obtained from Pharmacia,  Upsala, Sweden) was added and the mixture incubated  at 37°C 
for 1 hour with frequent stirring and then gently  rotated  on a Heller motor in the cold at 
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Antibody Fractionation Procedure 
9000/zg 20 Du, 12, 1~ antidextran  N 
+ 
500 mg sephadex G-75" (washed 4 times with buffered saline) 
220 m~'~'M~~mg  IM6 
3280/zg N  27.~30/xg N  116/zg N/ 
37 per cent IM3 Ab  32 per cent IM6 Ab 
69 per cent 
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about  10 ~  for 8  days. After centrifugation of the sephadex the superuatant  serum was 
found free of precipitating antidextran. The sephadex-antibody precipitate was then washed 
repeatedly with ~/1000  phosphate-buffered  saline pH  7.3  until  the washings  were free of 
protein measured at 2800 A. 
(b)  Fdution: Elufion of antibody fractions was carried out as shown in Table I using buffered 
saline  solutions  of isomaltotriose  and  then  of isomaltohexaose.  For  this  step  the  packed 
sephadex was transferred  into screw capped  bottles of "blood collecting outfits"  (available 
from Travis & Co., London). These consist of twin bottles that are connected top to top by 
a double threaded, sieve type metal piece that carries a Whatman 50 filter paper disc. After 
addition of hapten to the sephadex-antibody precipitate in one bottle, the mixture was placed 
in a 37°C water-bath for 1 hour with frequent inversion followed by slow rotation in the cold 
over night. The twin bottles were then centrifuged lightly and the eluate passed through the 
filter disc into the second bottle. The eluate was removed and the sephadex washed repeatedly 
in this manner with small amounts of buffered saline until no material absorbing at 2800 A 
could be detected. Before elution of the sephadex-anfibody precipitate with another oligosac- 
charide washings were continued until they were free of reducing sugar measured by the Park- 
Johnson  method  (cf. reference  7).  Eluates  and  washings  containing material  absorbing  at 
2800 A were combined and concentrated by ultrafiltration in the cold under negative pressure 
through  a  7  ml  collodion membrane  (membranfiltergeselischaft g6ttingen,  Schleicher and 
Schfill,  Keene, New Hampshire).  The concentrate was diluted with buffered saline and re- 
concentrated until the ultrafiltrates were free of reducing sugar. This technique for concentrat- 
ing the antibody fractions and for removal of hapten was much more rapid than the prolonged 
dialysis used earlier (1) and eliminated the pervaporation step. Total N in the antibody frac- 
tions was determined by a  modified ninhydrin  technique (8).  For determination of precipi- 
tating AbN an appropriate volume of purified fraction containing about 3 #g AbN was added 
to known quantities of dextran, the solutions were mixed and incubated at 37°C for 1 hour and 
in the cold for 1 week with daily mixing. The precipitates were centrifuged off, washed once 
with saline and analyzed for N after digestion with H2SO~  by the ninhydrin method (8). Small 
amounts of antidextran fractions 20 Da-IM3 Ab and 20 Ds-IM6 Ab (1) were available. 
De~trans.--Various  dextrans were used as described in earlier papers  (5, 9,  1). 
Oligosa~¢karid~.--The  isomaltose series of oligosaccharides were those prepared earlier (1). 
Quantitative  Micro¢omplement Fixation.--The  necessary  components  for  the  indicator 
system were purchased,  stored, and prepared for the assays as described by Wasserman and 
Levine (4). Experiments were set up in 40 ml centrifuge tubes in a total volume of 7 m/. The 
diluent was added with a "miscomatic dispenser" plastic bottle (available from Microchemical 
Specialties Company, Berkeley, California). Dilutions of antidextran serum, purified antibody 
fractions, and dextrans in the standard diluent (7) were measured with 1 ml analytical blow 
out pipets. An amount of freshly diluted guinea pig serum containing 1.3 to 1.6 C'I-I~0 (4) was 
added to the chilled tubes in ice water with a Cornwall automatic syringe. After 16 to 20 hours' 
incubation in the cold, 50 million washed sheep erythrocytes, previously sensitized with rabbit 
anti-sheep hemolysin for 15 minutes at 37°C,  were added to each tube. The titration  of the 
hemolytic rabbit antibody in this system revealed a  plateau type lysis curve, beginning at 
about 1:1500, which dilution was used throughout all the experiments (7). The reaction mix- 
tures with indicator system were then incubated at 37°C until the complement  containing 
control tubes showed approximately 90 per cent lysis or slightly less as compared to complete 
lysis of the tubes with excess complement. The mixtures after rapid chilling in an  ice bath 
were transferred  into smaller centrifuge tubes,  spun  at  1800 ~M for 10 minutes and  the 
superuatant  fluids analyzed for hemoglobin at 4120 A. 
Quantitative Microcomplement Fixation  Inhibition.--For  irdfibition  assays  the  oligosac- 
charides were first added to the tubes using Lang-Levy pipets and the volume made up with 986  HUMAN  AN'rIDEXTEAN  ANTIBODIES.  II 
diluent. Each determination was carried out in duplicate and fixation in absence of inhibitor 
was assayed in triplicate.  Controls for anticomplementary activity  of antibody solutions, 
dextrans, and haptens were always included. Per cent complement fixation was calculated as 
the difference between the amount of released hemoglobin of antigen-antibody mixtures and 
the blank of antibody incubated without dextran. Inhibition was expressed as per cent fixa- 
tion of reaction mixtures in presence of inhibitor compared to that in tubes without inhibitor. 
]~ESULTS 
Table I  is a flowsheet of the antibody fractionation procedure: A ratio of 56 
mg sephadex per mg AbN resulted in total absorption of the precipitating anti- 
dextran.  The recovery in the isomaltotriose extraction was 37  per cent,  and 
with isomaltohexaose an additional 32 per cent of the original antidextran  N 
was recovered; total yield 69 per cent. Both fractions were 95 to 100 per cent 
precipitable  by dextran. 
Complement Fixation with Purified Antidextran  Fractions.--The quantitative 
complement fixation curves obtained with the two purified 20 D11-13 fractions 
are shown in Figs.  1 A  and  1 B. Fig.  1 A  shows three curves with 20 Dn-13- 
IM6 Ab using three levels of AbN. On incubating 100 m~g AbN with various 
quantities  of dextran N  236 peak fixation of 40 per cent was obtained, while 
with 140 m/zg N  fixation rose to 78 per cent. At both these Ab levels inhibition 
of fixation occurred in antigen excess. With 280 mt~g AbN per reaction mixture 
the percentage complement fixed rose to 94 and the resulting  curve was fiat 
over a wide range. In Fig. 1 B the three corresponding quantitative complement 
fixation curves with similar amounts of 20 Dn.13-IM3 AbN and the same quan- 
tifies of dextran N  236  are given. It can be seen that the complement-fixing 
potency of this fraction was considerably lower since with 108 m~g AbN only 
5 per cent of the complement was fixed. With  182 m/zg there was 35 per cent 
fixation and with 321  mt~g AbN 80 per cent was fixed. The 20 Dn.~3-IM3 Ab 
gave a very narrow equivalence zone. Quantitative fixation curves of 282 m/zg 
of the 20 Dll.~3-IM6 Ab with a variety of dextrans are shown in Fig.  1 C. No 
complement fixation was found with  dextran N  150  N  (tool.  wt.  60,000  de- 
termined  by viscosity)  (cf.  reference  5).  Using  dextran  fractions  of  graded 
molecular weight, peak fixation of 52 per cent was obtained with NRC 8 (tool. 
wt.  412,000)  (cf. reference 9).  Fractions  of lower molecular weight gave less 
fixation and NRC 6  (mol. wt.  195,000)  (cf. reference 9) was the smallest size 
product with which this purified antibody fixed complement. 
Complement Fixation  with Antidextran  Sera.--The quantitative  complement 
fixation curves of human antidextran sera are shown in Fig.  1 D. Reproducible 
fixation was found with dextrans N  236 or B  512 using 250  to 320 m~g pre- 
cipitating AbN per reaction mixture.  Since most human antidextrans contain 
only between 5 to 35 t~g precipitating AbN per ml, low serum dilutions were 
necessary.  The anti-NRC  4  serum  of subject  176  required  prior  absorption 
with sheep ceils for removal of hemolysin. ~USTUS  GELZER  AND  ELVIN  A. KABAT  987 
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Quantitative Complement Fixation Inhibition Studies with Antidextran Serum 
20 Dln.--Fig. 2 shows quantitative complement fixation inhibition curves with 
the isomaltose series of oligosaccharides using 43 m~g N  236 and an amount of 
unfractionated antidextran  20 D16 containing approximately 300 mlzg  AbN. 
The ratios of inhibiting power of the various oligosaccharides were very similar 
to those observed by inhibition of precipitation (3, 6). Thus IM3 was a poor 
inhibitor and  only slightly better  than  IM2.  The greatest  increment in  in- 
hibiting power was found between IM3 and IM4. IM5, IM6, and IM7 were 
500  mvug Ab N  20 DI5  Anfi-  0P155  oO[ o 
|1  I  l~  /  a  Isomaltotriose  60 ['1 I  ~/  /  n  Isomaltotetraose  .-  =. 
J I  I  ~r  n/  (3 Isomoltopentaose  -.-----6" 
I Icl°/  tY  o  Isomaltohexaose  -  40~/  /  e  Isomaltoheptaose 
'  0,2'  ,  3  I~  01  I  I  I  I  I 
0,I  0.6  1,0  1,2 
MICROMOLES  OLIGOSACCHARIDE  ADDED 
FIO. 2. Inhibition by oligosaccharides of C' fixation of anfidextran serum 20 DI~ with 
dextran. 
progressively better inhibitors on a  molar basis than IM4,  the increment de- 
creasing with increasing chain length. 
Quantitative  Complement  Fixation Inhibition Studies with Purified Antibody 
Fractions.--Figs. 3 A  and 3 B  show the quantitative complement fixation in- 
hibition data with purified antibody fractions derived from bleeding  20  D3 
on which curves by inhibition of precipitation had already been obtained (1). 
398 m/~g 20 D3-IM3 AbN and 382 m/zg 20 D~-IM6 AbN with 43 m~g N  236 
were used per assay giving reproducible complement fixation of 76 to 88 per 
cent. The degree of inhibition in presence of a constant amount of hapten was 
constant in the zones of equivalence and slight antigen excess. The behavior of 
the 20 D~-IM3 Ab was strikingly different from that of the 20 D~-IM6 Ab: with 
the former IM2 inhibited substantially and inhibition was readily obtained with 
IM3. On the other hand with the IM6 Ab identical amounts of IM2 showed no .q 
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inhibition and IM3 inhibited almost negligibly over the range tested. With the 
20 D3-IM3 Ab, IM4 was a better inhibitor than IM3 and IM5 was better than 
IM4.  IM6 and IM7  were better than IM5  and  almost equally potent on a 
molar basis. With the 20 D3-IM6 Ab on the other hand IM7 was significantly 
better than IM6. 
In Figs. 3 C, 3 D, and 3 E  the curves with the purified fractions from more 
recent bleedings of subject  20 are represented. 305,  280,  and 300 m/zg  AbN 
respectively with 43 m/zg N  236 were found to fix comparable amounts of com- 
plement, approximately 80 per cent of the quantity of complement added. At 
the 50 per cent inhibition point IM3 and IM4 were shown more potent relative 
to IM6 in inhibiting complement fixation of 20 Dn.13-IM3 Ab than they were in 
inhibition of complement fixation of the  20 Dn.~-IM6  and -IM6  t  Ab.  Thus 
with the IM3 Ab the relative inhibiting power of IM3, compared to IM6, was 11 
per cent, whereas with the IM6  t  Ab fraction IM3  was  only 1.1  per  cent as 
effective as IM6. The curves obtained with IM4, IM5, and IM6 from the 20 
Du_~-IM3 Ab were superimposable with the corresponding ones from the IM3 
Ab prepared from the earlier bleeding D8 (Fig. 3 A). With the 20 Dn-13-IM6 Ab, 
IM6 was better than IM5 which in turn was better than IM4. Almost no in- 
hibition of complement fixation was obtained with IM2 and IM3 in the range 
tested. The same relationship of the various oligosaccharides to each other was 
found with  the  20  Dn.~a-IM6  ~ Ab.  IM7  was  the best inhibitor and  slightly 
better than IM6. The curves obtained with IMT, IM6,  IM5,  and IM4 were 
also superimposable within the limits of experimental error with those from 
the IM6-Ab of the earlier bleeding (Fig. 3 B). 
DISCUSSION 
The findings clearly show that purified human antidextran and some human 
antidextran sera fix guinea pig complement in presence of dextran. In earlier 
studies no difference in N  (of. reference 7) was found between specific precipi- 
tates  formed  in  undecomplemented  and  decomplemented  antidextran  sera 
(5).  To obtain reproducible fixation curves 250  to 400 m/~g of precipitating 
antidextran N  were required per  analysis with serum and purified antibody 
(Figs. 1 A  to 1 D). Variations in fixing potency of antidextran serum were due 
to sheep hemolysins present at the low dilutions of the antidextran sera used, 
enhancing the lyric susceptibility of the sheep cells.  Prior absorption of such 
sera abolished this variation  (Fig.  1 D).  Purified antidextran fractions were 
suitable for microcomplement fixation even when obtained from sera preserved 
with  phenol  and  merthiolate  for long  periods  and  which  had  become anti- 
complementary. With the two purified 20 Dn-18-Ab fractions definite differences 
in complement fixing potency were established. Approximately half the amount 
of 20 Dn-I~-IM6 AbN as of 20 Dn.13-IM3 AbN of equal purity was necessary 
to fix 40 per cent of the complement added in presence of dextran N  236 (Figs. 
1 A  and  1 B).  Moreover the 20 Dn.13-IM3 Ab showed rapid inhibition with JUSTUS  GELZER  AND  ELVIN  A.  KABAT  991 
moderate  antigen  excess which did not occur either  with  the  corresponding 
unfractionated antidextran  20 D16 (Fig.  1 D) and the 20 Dn.18-IM6 Ab (Fig. 
1 A). Similar  findings were obtained with the two antibody fractions from the 
20 D3 bleeding  (1). These differences between the two fractions reflect hetero- 
geneity of the antidextran  of a single individual in ability to fix complement. 
Approximately twofold differences  in complement fixing activity per #g AbN 
were reported  earlier  between first-  and  second-course rabbit  anti-BSA  sera 
using 100 C'Hs0 units (10). With first-course antisera the necessary range for 50 
per cent fixation  was 2 to 4/zg AbN per analysis whereas with second-course 
antisera 1/~g AbN produced 50 per cent and 2 #g about 70 to 90 per cent fixa- 
tion. The narrow equivalence zone  obtained with the 20 Du_~-IM3 Ab indi- 
cates that  extraction with IM3 yielded a  fraction  with reduced complement 
fixing  capacity. In  quantitative  precipitin  assays with low molecular weight 
NRC dextrans (1) the 20 D~-IM3 Ab was found to go into the inhibition  zone 
more readily than did the 20 D3-IM6 Ab. The basis for the difference in com- 
plement-fixing  potency is unknown. 
Studies on fractions of antibody obtained by papain digestion (11, 12) ascribe 
to fragment HI the binding site for complement on rabbit antibody while the 
antibody combining sites are on fragments I  and II (13-15; cf.  reference 16). 
With human antibody the complement-fixing  site is thought to be on the F(B) 
(cf.  reference 16) and the antibody combining  sites were shown to be on the 
S(A and C) fragments (17). Thus the site for complement binding might be re- 
mote from the antibody combining sites. However the antigen-antibody bonds 
which are unaffected by papain digestion appear to affect the complement fix- 
ing properties. Schur and Becker (18) found that washed specific precipitates 
of pepsin digested 5 S rabbit antibody (cf.  reference 19) and egg albumin fixed 
complement well although peptic digestion is accepted as destroying fragment 
III.  Subsequently Reiss  and  Plescia  (20)  showed  that  human  complement 
which had been fixed on to Ea-rabbit anti-Ea specific precipitates remained 
fixed after removal of fragment III by papain digestion.  The present finding 
that the IM3-Ab is only half as effective per unit weight in complement fixation 
as  the  IM6-Ab  indicates  that  the  antibody-comblning  site  is  involved  in 
strength of the complement fixation.  The two purified  antibody fractions are 
identical in mobility range  in immunoelectrophoretic  analysis  (1),  both give 
essentially the same pattern in starch gel electrophoresis  after reduction and 
alkylation  (21);  moreover  the  whole  antidextran  of  individual  20  D  was 
Gm(a--b+) which corresponds to his whole serum Gm grouping (22). The two 
fractions were also found to sensitize  the guinea pig for passive cutaneous ana- 
phylaxis, the IM3-Ab being slightly poorer than the IM6-Ab (23), the property 
of attaching to guinea pig skin also being associated with fragment III (24, 25). 
How the interaction of antigen with antibody influences complement binding to 
fragment III in intact gamma globulin requires further study. 
The  quantitative  complement fixation  studies with  20 Dn-u-IM6  Ab and 992  HUMAN  ANTIDEXTRAN  ANTIBODIES.  II 
dextrans of various molecular weights (Fig.  1 C) established that a decrease in 
molecular weight of the antigen causes a significant  decrease in the amount of 
complement fixed. The smallest fraction, NRC 6, giving  appreciable comple- 
ment fixation,  has a  molecular weight of 195,000. In quantitative precipitin 
studies with antidextran sera, however, NRC 1 with a molecular weight as low 
as 10,600 precipitated about ~  of the antibody N and fractions with molecular 
weights of 50,000 or above precipitated as much antibody as did native dextran 
(9). Small differences in quantitative precipitin curves between purified  20 D3- 
IM3 Ab and 20 D~-IM6 Ab with graded molecular weight dextrans were re- 
ported (1). NRC 1 (tool. wt. 10,600) and NRC 2B (mol. wt. 35,000) precipi- 
tated somewhat less antibody than did NRC 7 (tool. wt. 255,000). In the com- 
plement fixation assay, on the other hand, differences between NRC 8, 7, 6 were 
measurable. In studies on human sera from patients with lupus erythematosus 
decreased complement fixation accompanied large decreases in molecular weight 
of the DNA used (26, 27). Extensive boiling and sonic disruption of DNA re- 
sulted in lowered complement fixation,  if the decrease in molecular weight was 
more than four-fold (27). 
Previous studies have shown that antidextran from a single individual could 
be separated into two antibody portions of similar purity by absorption of the 
antidextran to sephadex followed by elution with haptens of increasing  size (1). 
The experiments reported above have confirmed that despite minor differences 
in the antibody purification  technique, an essentially identical fractionation of 
antidextran  from later  bleedings  of the same individual  resulted.  Moreover 
quantitative  microcomplement  fixation  assays  gave  findings  comparable  to 
those by the quantitative precipitin inhibition technique (of.  reference  1, Figs. 
2 C and 2 D). 
Thus the results provide further evidence that the 20 Da-IM3 Ab consisted 
largely of molecules with a higher afliuity for smaller  oligosaccharides  and pre- 
sumably contained  relatively  few  antibody molecules  with  combining  sites 
larger than a pentasacchadde. On the other hand the 20 Da-IM6 Ab consisted 
chiefly of molecules with affinity for larger oligosaccharides  and hence these are 
inferred to possess larger size combining sites. Thus with this fraction IM7 was 
definitely superior to IM6 which was better than IM5 which in turn was con- 
siderably better than IM4. IM3 and IM2 were extremely poor inhibitors. 
The separation of antidextran from single individuals into two populations of 
antibody molecules  provides further indications that  the increased inhibiting 
power of the higher oligosaccharides is specifically related to the combining site. 
Metzger, Wofsy, and Singer  (28) have recently questioned this interpretation 
by attributing increased inhibition by larger sized haptens to non-specific inter- 
actions making cooperative contributions to the overall free energy. The present 
findings  indicate that  the complement-fixing  properties of the two antibody 
fractions as well as their capacity to be inhibited by oligosaccharides  of various ~0"STUS  GELZER  AND  ELVIN  A.  KABAT  993 
sizes differ significantly. To maintain the interpretation of Metzger eta/. (28), 
one would be forced to assume that the hypothesized non-specific contribution 
to binding energy by the oligosaccharides is not the same for all of the antibody 
molecules. Moreover earlier studies have shown that a change in linkage of the 
third to the fourth glucose ring as in 4-O-tx isomaltotriosyl-D-glucose produced 
a definite decrease in inhibiting power as compared with isomaltotriose (29, 30). 
Thus the supposed non-specific interaction shows at least a remarkable speci- 
ficity for the al, 6 linkage at the fourth glucose. While it is possible that minor 
non-specific effects occur attributable to the fifth, sixth, and seventh glucose 
units, it is apparent that the increased inhibitory power up to at least the tetra- 
saccharide is predominantly related to the size of the antibody combining site. 
This is further supported by the recent findings (31) that the portion of type 
XXH antipneumococcal antibody cross-reacting with dextran could be further 
fractionated into two populations of cross-reacting antibody molecules. With 
one fraction, the isomaltose oligosaccharides showed increasing inhibiting ca- 
pacity on a molar basis up to isomaltohexaose and isomaltoheptaose which were 
equal and the best inhibitors. The second fraction gave maximum inhibition 
with isomaltose and kojibiose and all isomaltose oligosaccharides from isomal- 
totriose to isomaltohexaose were equal in inhibiting power to isomaltose. Once 
again one would be forced to attribute to individual antibody molecules differ- 
ences in capacity to react non-specifically to chains of al, 6 linked glucoses to 
maintain the interpretation of Metzger eta/. (28). 
Although the relative inhibiting capacities of the various oligosaccharides to 
one another in each fraction was the same for inhibition of precipitation and of 
complement fixation, the amount of inhibitor necessary for 50 per cent inhibi- 
tion relative to the amount of AbN used was much greater for complement 
fixation inhibition. Similar findings were reported in the rabbit anti-SXIV im- 
mune system (4). 
SUMMARY 
Human antidextran of one individual,  absorbed  specifically on  sephadex, 
was fractionated into two populations of antibody molecules by successive elu- 
tion with oligosaccharides of the isomaltose series of increasing size. The purified 
antibody fractions and some whole antidextran sera were found to fix comple- 
ment with dextrans of molecular weight of 195,000  and above. 
It could be demonstrated by quantitative microcomplement fixation inhibi- 
tion assays that the antibody eluted with isomaltotriose had a higher affinity 
for smaller oligosaccharides relative to isomaltohexaose, indicating a high con- 
tent of antibody molecules with smaller combining sites, while with the second 
fraction, eluted with isomaltohexaose, the small haptens were very poor inhibi- 
tors  and  the  larger  oligosaccharides  inhibited  readily,  presumably  due  to 
a higher proportion of molecules with larger combining site size. Assays of simi- 994  HUMAN  AlqTIDEXTRAN  ANTIBODIES.  II 
larly prepared fractions, obtained from earlier bleedings of the same individual 
(1), with inhibition of complement fixation were in good agreement with those 
obtained by inhibition of precipitation. 
The two purified antidextran fractions were shown to differ with respect to 
their  complement-fixing capacity. The  fraction with molecules with smaller 
size-combining sites fixed only about haft as much complement per unit anti- 
body N  as did the fraction containing largely molecules with larger combining 
sites suggesting that the strength of complement fixation is  affected by the 
strength of the antigen-antibody interaction. 
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